InMed Pharmaceuticals Inc (IN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:InMed Pharmaceuticals Inc (IN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013253
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
InMed Pharmaceuticals Inc (InMed), formerly Cannabis Technologies Inc, is a pre-clinical stage biopharmaceutical company which develops, produces and markets plant cannabinoid based pharmaceutical products to related healthcare markets. The company’s pipeline products include INM-750 and INM-085. Its products are used for the treatment of glaucoma, ocular allergies, arthritis, cancer and skin diseases, epidermolysis bullosa, psoriasis and pemphigus vulgaris metabolic syndrome, among others. InMed uses its proprietary platform technology to discover new bioactive compounds within the cannabis plant that interact with certain genes responsible for specific diseases. The company works in partnership with University of British Columbia and University of Debrecen. InMed is headquartered in Vancouver, British Columbia, Canada.

InMed Pharmaceuticals Inc (IN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
InMed Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
InMed Pharma Enters into Research and Development Agreement with ATERA 13
InMed Pharma Enters into Agreement with Pharmaseed 14
Revive Therapeutics to Enter into Agreement with InMed Pharma 15
InMed Pharma Enters into Agreement with University of Debrecen to Develop Novel Phytocannabinoid Therapies for Ocular Allergies 16
InMed Pharma Enters into Agreement with University of British Columbia 17
Cannabis Science Enters into Co-Development Agreement with ImmunoClin 18
Cannabis Science Enters Into Joint Venture With Dupetit Natural Products 19
Cannabis Science Enters Into Co-Development Agreement With UF4A 20
Licensing Agreements 21
Cannabis Science Enters Into Licensing Agreement With Endocan 21
Cannabis Science Enters Into Licensing Agreement With Rockbrook 22
Equity Offering 23
InMed Pharma Raises USD4.3 Million in Public Offering of Units 23
InMed Pharma Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 25
InMed Pharma to Raise USD1 Million in Private Placement of Units 26
InMed Pharma Raises USD0.2 Million in Private Placement of Units 27
InMed Pharma to Raise USD0.7 Million in Private Placement of Units 28
InMed Pharma Raises USD0.83 Million in Private Placement of Units 29
InMed Pharma Raises USD0.8 Million in Private Placement of Units 30
Cannabis Science Raises USD1 Million in Private Placement of Shares 31
Asset Transactions 32
X-Change Acquires Phytiva Brand Of Products From Cannabis Science 32
Acquisition 33
Cannabis Science to Acquire Canada-Based Medical Cannabis Provider 33
Cannabis Science to Acquire Additional 30.1% Stake in Michigan Green Technologies 34
X-Change Acquires Germany-Based Joint Venture Company From Cannabis Science And Dupetit Natural Products 35
Cannabis Science Acquires Trimcare, Provider Of Healthcare Facilities 36
InMed Pharmaceuticals Inc – Key Competitors 37
InMed Pharmaceuticals Inc – Key Employees 38
InMed Pharmaceuticals Inc – Locations And Subsidiaries 39
Head Office 39
Recent Developments 40
Corporate Communications 40
Oct 10, 2017: InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board 40
Jan 13, 2017: InMed Pharmaceuticals Appoints Martin Bott to Board of Directors 41
Dec 15, 2016: InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier 42
Sep 13, 2016: InMed Appoints Andrew Hull to the Board of Directors 43
Jun 16, 2016: InMed Announces Appointment of Eric A. Adams as CEO, President and Director 44
Jun 13, 2016: InMed Announces Appointment of William J. Garner, M.D. to its Board of Directors 45
Product News 46
Oct 24, 2017: InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid 46
Feb 16, 2016: InMed Announces Update on Biosynthesis Project 47
Clinical Trials 48
Oct 17, 2017: InMed Updates Pain Program 48
May 18, 2016: InMed Updates Progress of its Epidermolysis Bullosa Program 49
Other Significant Developments 50
Dec 23, 2016: InMed Provides 2016 Year End Update 50
May 04, 2016: InMed Pharmaceuticals Provides Strategic Update on its Business Plans, Announces Planned Executive and Board Departures 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
InMed Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
InMed Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
InMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
InMed Pharma Enters into Research and Development Agreement with ATERA 13
InMed Pharma Enters into Agreement with Pharmaseed 14
Revive Therapeutics to Enter into Agreement with InMed Pharma 15
InMed Pharma Enters into Agreement with University of Debrecen to Develop Novel Phytocannabinoid Therapies for Ocular Allergies 16
InMed Pharma Enters into Agreement with University of British Columbia 17
Cannabis Science Enters into Co-Development Agreement with ImmunoClin 18
Cannabis Science Enters Into Joint Venture With Dupetit Natural Products 19
Cannabis Science Enters Into Co-Development Agreement With UF4A 20
Cannabis Science Enters Into Licensing Agreement With Endocan 21
Cannabis Science Enters Into Licensing Agreement With Rockbrook 22
InMed Pharma Raises USD4.3 Million in Public Offering of Units 23
InMed Pharma Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 25
InMed Pharma to Raise USD1 Million in Private Placement of Units 26
InMed Pharma Raises USD0.2 Million in Private Placement of Units 27
InMed Pharma to Raise USD0.7 Million in Private Placement of Units 28
InMed Pharma Raises USD0.83 Million in Private Placement of Units 29
InMed Pharma Raises USD0.8 Million in Private Placement of Units 30
Cannabis Science Raises USD1 Million in Private Placement of Shares 31
X-Change Acquires Phytiva Brand Of Products From Cannabis Science 32
Cannabis Science to Acquire Canada-Based Medical Cannabis Provider 33
Cannabis Science to Acquire Additional 30.1% Stake in Michigan Green Technologies 34
X-Change Acquires Germany-Based Joint Venture Company From Cannabis Science And Dupetit Natural Products 35
Cannabis Science Acquires Trimcare, Provider Of Healthcare Facilities 36
InMed Pharmaceuticals Inc, Key Competitors 37
InMed Pharmaceuticals Inc, Key Employees 38

★海外企業調査レポート[InMed Pharmaceuticals Inc (IN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AIG Europe Limited:企業の戦略・SWOT・財務情報
    AIG Europe Limited - Strategy, SWOT and Corporate Finance Report Summary AIG Europe Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Maquet Holding BV & Co KG:企業の戦略的SWOT分析
    Maquet Holding BV & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • University of Bristol-製薬・医療分野:企業M&A・提携分析
    Summary University of Bristol (UOB) is an educational service provider that offers undergraduate and postgraduate courses and research services. The university offers courses in arts, biomedical sciences, engineering, medical and veterinary sciences, dentistry, science, and social sciences and law. …
  • The Kansai Electric Power Co, Incorporated:企業の戦略・SWOT・財務分析
    The Kansai Electric Power Co, Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Kansai Electric Power Co, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Univalor-製薬・医療分野:企業M&A・提携分析
    Summary Univalor is a university technology transfer organization which optimizes research outcomes by commercializing the technological innovations of researchers from academic institutions and health centers. The organization offers researcher services such as evaluating the technical feasibility …
  • A. Menarini Diagnostics Srl:医療機器:M&Aディール及び事業提携情報
    Summary A. Menarini Diagnostics Srl (Menarini Diagnostics), a subsidiary of A Menarini Industrie Farmaceutiche Riunite Srl is a medical device company that offers in-vitro diagnostic products. The company provides pharmaceutical testing products including home glucose testing products, oral anticoag …
  • HemaCare Corp (HEMA)-医療機器分野:企業M&A・提携分析
    Summary HemaCare Corp (HemaCare) is a provider of biological blood products and services. The company offers primary blood cells and tissues derived from normal and mobilized peripheral blood, bone marrow and cord blood. It spans its expertise in isolations, custom cell collections and testing of pr …
  • Steven Madden Ltd (SHOO):企業の財務・戦略的SWOT分析
    Steven Madden Ltd (SHOO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Portland General Electric Co:企業の発電所・SWOT分析2018
    Portland General Electric Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Atlas Iron Ltd:企業のM&A・事業提携・投資動向
    Atlas Iron Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Atlas Iron Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Korean Reinsurance Company:企業の戦略・SWOT・財務情報
    Korean Reinsurance Company - Strategy, SWOT and Corporate Finance Report Summary Korean Reinsurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Chunghwa Post Co., Ltd.:企業の戦略・SWOT・財務分析
    Chunghwa Post Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chunghwa Post Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Super Dragon Technology Co., Ltd. (9955):企業の財務・戦略的SWOT分析
    Super Dragon Technology Co., Ltd. (9955) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Sinclair Broadcast Group, Inc.:企業の戦略・SWOT・財務分析
    Sinclair Broadcast Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sinclair Broadcast Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hookipa Biotech AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Hookipa Biotech AG (Hookipa) is a biotechnology company that develops vaccines and next-generation immunotherapeutics for the prevention and treatment of cancer and infectious diseases. The company's lead product candidate include HB101 vaxwave, a vaccine under development for immunization a …
  • Integra LifeSciences Holdings Corp (IART)-医療機器分野:企業M&A・提携分析
    Summary Integra LifeSciences Holdings Corp (Integra) is a medical technology company. Integra’s orthopedics products comprise specialty metal implants, dermal regeneration products, orthobiologic products, tissue-engineered wound dressings, and nerve and tendon repair products. The company’s neurosu …
  • Clinipace Worldwide Inc:医療機器:M&Aディール及び事業提携情報
    Summary Clinipace Worldwide Inc (Clinipace), formerly Clinipace Inc is a contract research organization that offers drug and medical devices development services. The organization’s services include manufacturing and control, chemistry, biostatistics, clinical monitory, data management, global study …
  • ATLAS Oil Company:石油・ガス:M&Aディール及び事業提携情報
    Summary ATLAS Oil Company (ATLAS) is an oil and gas company that offers fuel supply and logistic services. The company’s services comprise supply, renewable fuels, bulk fueling, fuel on demand, logistics, fixed price contracts, frac site fueling, emergency refuel, crude hauling, transloading and on- …
  • viDA Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary viDA Therapeutics Inc (viDA) is a biopharmaceutical company that discovers, develops and commercializes novel and targeted therapeutics for the treatment of autoimmune and age-related chronic inflammatory diseases. The company’s lead product candidate include VTI-1002, is in a topical formul …
  • QDVC Q.S.C:企業の戦略的SWOT分析
    QDVC Q.S.C - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆